Low
₹1,778.30
High
₹1,870.00
| Previous Close | ₹1,830.20 |
|---|---|
| Day's Range | ₹1,778.30 - ₹1,870.00 |
| Open | ₹1,809.90 |
| 52 Week Range | ₹1,057.00 - ₹2,248.00 |
| Volume | 3,53,920 |
| Market Cap | ₹0.02 |
| Trade Value ( ₹ in Lacs) | 6,422.67 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 1045.68 |
| TTM EPS (₹) | 1.75 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 3.61 |
| PAT Margin (%) | -1.20 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 2.61 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 3367.49 | 1719.19 |
| Expenses | N/A | N/A |
| PBT | -730.23 | -3649.34 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -730.23 | -3904.02 |
| Founded | 2007 |
|---|---|
| Managing Director | Neeraj Sharma |
| NSE Symbol | ONESOURCE |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,42,893.24 | 1,845.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,76,366.71 | 6,637.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,48,240.79 | 4,380.05 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,15,309.54 | 8,025.00 | 6,696.50 - 6,696.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,009.78 | 1,270.10 | 1,143.90 - 1,143.90 |
| Cipla Ltd. | 1,04,365.52 | 1,295.15 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,02,690.68 | 2,240.70 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 99,183.27 | 1,017.65 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 98,147.87 | 2,377.45 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 93,655.23 | 932.00 | 835.50 - 835.50 |
No Records Found
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, OneSource Specialty Pharma has informed that NSE Sustainability Ratings & Analytics (‘NSE Sustainability’) has, independently assigned Environmental, Social and Governance (‘ESG’) Rating of ‘73’ (Rating Category: Leader) to the Company for the financial year FY25. The Company has not engaged NSE Sustainability for ESG Rating exercise. The rating has been independently assigned by NSE Sustainability based on information pertaining to FY25 of the Company available in the public domain. This intimation is in accordance with the SEBI Master Circular no. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30,2026.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 read with read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘Listing Regulations’), OneSource Specialty Pharma has informed that SES ESG Research (SES ESG) has assigned an Environmental, Social, and Governance (ESG) score of 65.7 vide its report received by the Company on 11th February 2026, based on FY 2024-25 data available in the public domain. The Company had not engaged SES for the ESG Rating. SES has independently prepared the report based on data pertaining to the Company available in public domain. This intimation is in accordance with the SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Onesource Specialty Pharma Ltd. is ₹1,830.20 as of 2026-05-12.
The market capitalisation of Onesource Specialty Pharma Ltd. is ₹21,020.30 as of 2026-05-12.
The 1-year return of Onesource Specialty Pharma Ltd. is 0.00% as of 2026-05-12.
The P/E ratio of Onesource Specialty Pharma Ltd. is 0.00 as of 2026-05-13.
The 52-week high and low of Onesource Specialty Pharma Ltd. are ₹2,248.00 and ₹1,057.00, respectively, as of 2026-05-12.
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.